NONOPIOID TREATMENTS FOR CHRONIC PAIN

Principles of Chronic Pain Treatment

Patients with pain should receive treatment that provides the greatest benefit. Opioids are not the first-line therapy for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. Evidence suggests that nonopioid treatments, including nonopioid medications and nonpharmacological therapies, can provide relief to those suffering from chronic pain and are safer.

Effective approaches to chronic pain should:

- Use nonopioid therapies to the extent possible
- Identify and address co-existing mental health conditions (e.g., depression, anxiety, PTSD)
- Focus on functional goals and improvement, engaging patients actively in their pain management
- Use disease-specific treatments when available (e.g., triptans for migraines, gabapentin/pregabalin/duloxetine for neuropathic pain)
- Use first-line medication options preferentially
- Consider interventional therapies (e.g., corticosteroid injections) in patients who fail standard non-invasive therapies
- Use multimodal approaches, including interdisciplinary rehabilitation for patients who have failed standard treatments, have severe functional deficits, or psychosocial risk factors

NONOPIOID MEDICATIONS

<table>
<thead>
<tr>
<th>Medication</th>
<th>Magnitude of Benefits</th>
<th>Harms</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>Small</td>
<td>Hepatotoxic, particularly at higher doses</td>
<td>First-line analgesic, probably less effective than NSAIDs</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>Small-moderate</td>
<td>Cardiac, GI, renal</td>
<td>First-line analgesic, COX-2 selective NSAIDs less GI toxicity</td>
</tr>
<tr>
<td>Gabapentin/pregabalin</td>
<td>Small-moderate</td>
<td>Sedation, dizziness, ataxia</td>
<td>First-line agent for neuropathic pain; pregabalin approved for fibromyalgia</td>
</tr>
<tr>
<td>Tricyclic antidepressants (TCAs) and serotonin/norepinephrine reuptake inhibitors (SNRIs)</td>
<td>Small-moderate</td>
<td>TCAs have anticholinergic and cardiac toxicities; SNRIs safer and better tolerated</td>
<td>First-line for neuropathic pain; TCAs and SNRIs for fibromyalgia, TCAs for headaches</td>
</tr>
<tr>
<td>Topical agents (lidocaine, capsaicin, NSAIDs)</td>
<td>Small-moderate</td>
<td>Capsaicin initial flare/burning, irritation of mucus membranes</td>
<td>Consider as alternative first-line, thought to be safer than systemic medications. Lidocaine for neuropathic pain, topical NSAIDs for localized osteoarthritis, topical capsaicin for musculoskeletal and neuropathic pain</td>
</tr>
</tbody>
</table>

Learn more: poison.health.ok.gov
RECOMMENDED TREATMENTS FOR COMMON CHRONIC PAIN CONDITIONS

**Osteoarthritis**

**Nonpharmacological treatments:** Exercise, weight loss, patient education

**Medications:**
- First-line: Acetaminophen, oral nonsteroidal anti-inflammatory drugs (NSAIDs), topical NSAIDs
- Second-line: Intra-articular hyaluronic acid, capsaicin (limited number of intra-articular glucocorticoid injections if acetaminophen and NSAIDs insufficient)

**Low Back Pain**

**Self-care and education in all patients:** Advise patients to remain active and limit bedrest

**Nonpharmacological treatments:** Exercise, cognitive behavioral therapy, interdisciplinary rehabilitation

**Medications:**
- First-line: Acetaminophen, NSAIDs
- Second-line: SNRIs, TCAs

**Migraine**

**Preventive treatments:**
- Beta-blockers
- TCAs
- Antiseizure medications
- Calcium channel blockers
- Nonpharmacological treatments (cognitive behavioral therapy, relaxation, biofeedback, exercise therapy)
- Avoid migraine triggers

**Acute treatments:**
- Aspirin, acetaminophen, NSAIDs (may be combined with caffeine)
- Antinausea medication
- Triptans (migraine specific)

**Fibromyalgia**

**Patient education:** Address diagnosis, treatment, and the patient’s role in treatment

**Nonpharmacological treatments:** Low-impact aerobic exercise (e.g., brisk walking, swimming, water aerobics, or bicycling), cognitive behavioral therapy, biofeedback, interdisciplinary rehabilitation

**Medications:**
- FDA-approved: Pregabalin, duloxetine, milnacipran
- Other options: Tricyclic antidepressants (TCAs), gabapentin

**Neuropathic pain**

**Medications:**
- TCAs, serotonin and norepinephrine reuptake inhibitors (SNRIs), gabapentin/pregabalin, topical lidocaine

Learn more: poison.health.ok.gov

This publication was supported by the Cooperative Agreement Number 5 NU17CEB002745-02 funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. The Oklahoma State Department of Health (OSDH) is an equal opportunity employer and provider. This publication, issued by the OSDH, was authorized by Terry L. Cline, PhD, Commissioner of Health, Secretary of Health and Human Services. 15,000 copies were printed by OKC Digital at a cost of $463.49. Copies have been deposited with the Publications Clearinghouse of the Oklahoma Department of Libraries and are available for download at www.health.ok.gov. August 2017. Adapted with permission from the Centers for Disease Control and Prevention.